Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin + Favipiravir in Mild-to-moderate COVID-19
NCT05155527Phase 2Unknown
- Sponsor
- Mahidol University
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CHILD-IVITAB in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mahidol University. Primary endpoint: The rate of SARS-CoV-2 viral clearance. Status: unknown.
02
Drugs
CHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05155527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155527.